Main info

Identifier:

HO131 MM / IFM 2015-01 (Cassiopeia)

Sponsor:

IFM

Working group party:

Myeloma

Age:

18-65

Stage:

1st Line

Echelon:

Limited Site Selection

Included patients:

176

(of 300)

Active sites:

0

(of 29)

Title:

Study of Daratumumab (JNJ-54767414 (HuMax® CD38) in Combination with Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects with Newly Diagnosed Multiple Myeloma.

Timeline

Flow

Details

Phase:

Prospective randomized Phase III study

Monitoring Type:

Study Specific

Objectives: